Hey, Mike, thank you very much and good morning, everyone. Welcome. Again, we are pleased to report that GAIN had another good quarter for fiscal year ‘23. This follows on the previous solid first quarter of the fiscal year. We clearly are in a challenging period with rising interest rates and inflationary costs. However, our portfolio companies were happy to say are meeting these challenges. And as a result, we ended the second quarter of fiscal year ‘23, which was on 9/30/22 with adjusted NII of $0.29 per share and total investments at fair value of $738 million, which is up from $690 million at 6/30/22. Our deal activity this quarter was fairly good as we made one new acquisition and investing $39 million. We also invested $30 million and recapitalized one of our existing portfolio companies. Now in connection with this investment, we received a return of our preferred equity investment of $10 million. We received dividend and success fee income of $4.8 million and recognized a realized gain of $2.2 million, thereby increasing our debt investment in that company when the dust settled to $57.7 million. So again, we were able to generate capital gains, fee income and indeed increase our actual investment in this portfolio company. I should note that we will have opportunity for recapitalizations from time to time. Now these are positive events as they generally allow us to generate capital gains and other income while increasing our investment in a company, where clearly we know the management team and the business. So, it’s a good opportunity. With the buyout market still frothy meaning relatively expensive and pretty competitive, this is a good way for us to create value within the portfolio and therefore reward shareholders. Now subsequent to the quarter end, we invested an additional $8.4 million to fund an add-on acquisition to one of our portfolio companies. Also subsequent to the quarter end, we announced a 6.7% increase in our monthly dividend to $0.08 per share – excuse me, up from $0.075 per share for a new annual run-rate of $0.96 per share. Additionally, we declared a supplemental distribution of $0.12 per share, which will be paid in December of 2022. We currently anticipate being able to fund future supplemental distributions and this comes as we recognize realized gains – excuse me, realized cap gains on the equity portion of future exits and potentially from other recapitalizations that we might do. Our bio-focused strategy continues to successfully generate both income from monthly distributions to shareholders and capital gains on equity for supplemental distributions. Now, we did experience a small decline in valuations in the aggregate across our portfolio and this was primarily as a result of declining valuation multiples, even though we had increases in EBITDA at many of our portfolio companies. Our balance sheet continues to be strong with loan leverage and a very positive liquidity position with significant availability near credit facility and you will hear a lot more about this from Rachael Easton, our CFO. This allows us to continue providing support to our portfolio companies for add-on acquisitions and interim financing if the need arises, while actively seeking new buyout opportunities and growing our assets. So looking forward, even though there does seem to be some moderation in the multiples being used to determine the values of buyouts, the market is still very competitive with deal flow being strong and significant liquidity in buyout funds, of course, who is our competition. We will remain patient and selective in our due diligence and review process, while aggressively seeking new acquisitions and implementing recapitalizations with existing portfolio companies as appropriate. I will let you know that the new acquisition effort is very important and is a high priority for us. So in summing up the quarter and looking forward, we believe the state of our portfolio is very good. We have a strong liquid balance sheet and active level of buyout activity and continued prospect of good earnings and distributions over the next year. So Rachael, would you tell us a little bit more detail about all of that?